Equities analysts expect Bruker Co. (NASDAQ:BRKR) to post earnings of $0.49 per share for the current quarter, according to Zacks. Seven analysts have provided estimates for Bruker’s earnings, with the highest EPS estimate coming in at $0.50 and the lowest estimate coming in at $0.47. Bruker posted earnings per share of $0.46 in the same quarter last year, which would suggest a positive year over year growth rate of 6.5%. The company is expected to report its next earnings report on Monday, February 12th.
According to Zacks, analysts expect that Bruker will report full-year earnings of $1.19 per share for the current year, with EPS estimates ranging from $1.18 to $1.20. For the next fiscal year, analysts anticipate that the business will report earnings of $1.34 per share, with EPS estimates ranging from $1.29 to $1.42. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Bruker.
Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.02. The company had revenue of $435.60 million for the quarter, compared to analyst estimates of $415.45 million. Bruker had a return on equity of 25.83% and a net margin of 8.85%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 earnings per share.
Institutional investors have recently made changes to their positions in the company. AJO LP acquired a new position in Bruker during the 2nd quarter worth about $46,075,000. First Trust Advisors LP lifted its stake in Bruker by 1,689.7% during the 3rd quarter. First Trust Advisors LP now owns 502,159 shares of the medical research company’s stock worth $14,939,000 after acquiring an additional 474,101 shares in the last quarter. Prudential Financial Inc. lifted its stake in Bruker by 292.8% during the 3rd quarter. Prudential Financial Inc. now owns 567,002 shares of the medical research company’s stock worth $16,868,000 after acquiring an additional 422,660 shares in the last quarter. Koch Industries Inc. lifted its stake in Bruker by 2,573.5% during the 2nd quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock worth $324,000 after acquiring an additional 322,252 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Bruker during the 2nd quarter worth about $6,806,000. 65.60% of the stock is currently owned by institutional investors and hedge funds.
Bruker (NASDAQ:BRKR) traded down $0.76 during midday trading on Friday, reaching $34.75. The company’s stock had a trading volume of 662,787 shares, compared to its average volume of 493,026. The firm has a market capitalization of $5,410.00, a price-to-earnings ratio of 36.97, a P/E/G ratio of 2.71 and a beta of 1.12. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60. Bruker has a one year low of $21.83 and a one year high of $36.53.
The firm also recently declared a quarterly dividend, which was paid on Friday, December 22nd. Stockholders of record on Monday, December 4th were paid a $0.04 dividend. This represents a $0.16 annualized dividend and a dividend yield of 0.46%. The ex-dividend date was Friday, December 1st. Bruker’s dividend payout ratio (DPR) is presently 17.02%.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.com-unik.info/2018/01/10/0-49-eps-expected-for-bruker-co-brkr-this-quarter.html.
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.